<DOC>
	<DOCNO>NCT01421966</DOCNO>
	<brief_summary>Chronic foot ulcer particularly prevalent patient underlie diabetes mellitus . These ulcer report leading cause hospitalization among people diabetes . The purpose study evaluate CureXcell® treat chronic low extremity ulcer adults diabetes mellitus . CureXcell® cell base therapy , contain activate homologous white blood cell prepare donate healthy whole blood . A total 280 patient randomize receive either CureXcell® sham .</brief_summary>
	<brief_title>Evaluation CureXcell® Treating Lower Extremity Chronic Ulcers Adults With Diabetes</brief_title>
	<detailed_description>Chronic foot ulcer particularly prevalent patient underlie diabetes mellitus . The prevalence diabetes mellitus grow epidemic rate Europe , United States general worldwide . Foot ulceration serious complication diabetes mellitus associate increase risk infection , gangrene amputation . These ulcer report leading cause hospitalization among people diabetes . Despite exist ulcer therapy technology , continue great necessity new wound healing technology improve heal rate chronic ulcer remain major source morbidity , concern , cost . This Phase 3 multinational , multicenter , randomize , double-blind , control study design evaluate CureXcell® treat low extremity chronic ulcer adult Diabetes Mellitus . CureXcell® cell base therapy obtain donated whole blood . The blood collect healthy , young adult ( age 18-40 ) , cell separate activated hypo-osmotic shock . A total 280 patient , approximately 35 site US , Canada Israel , randomize receive either CureXcell® control . The primary objective study evaluate clinical benefit CureXcell® ( study biologic ) compare control , adjunct Good Ulcer Care . Additional objective demonstrate safety , tolerability durability CureXcell® compare control . The study two phase : core double-blind phase follow phase .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<criteria>1 . Males female least 18 year age diabetes type 1 type 2 ; 2 . Patients HbA1c ≤ 12 % ; 3 . Patients least one low extremity ( malleolus ( ankle bone ) ) , least fullthickness ulcer ( penetrate whole layer skin ) , unresponsive treatment least 4 week ; 4 . Ulcers area ≥ 1 cm2 ≤ 20 cm2 ( sharp debridement free , nonviable , hyperkeratotic fibrotic tissue extent possible ) ; 5 . Ankle Brachial Index ≥ 0.65 ; 1 . Patients two ulcer foot total three chronic ulcer ; 2 . Patients ulcer primarily cause venous insufficiency ; 3 . Patients whose target ulcer decrease &gt; 25 % size screen baseline ; 4 . Malignancy within past 5 year exclude successfully treat basal cell carcinoma ; 5 . Significantly compromise immunity reason include radiation therapy , chemotherapy HIV ; 6 . Current clinical osteomyelitis ; 7 . Acute Charcot foot ; 8 . Current sepsis ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>chronic ulcer</keyword>
	<keyword>diabetic foot ulcer</keyword>
</DOC>